Prostate Cancer Prevention by Sulforaphane, a Novel Dietary Histone Deacetylase Inhibitor
Annual rept. 1 Jan-31 Dec 2007
OREGON STATE UNIV CORVALLIS
Pagination or Media Count:
Prostate cancer is the second leading cause of cancer related death in men. To test Sulforaphane SFN as a novel histone deacetylases HDAC inhibitor and explore the mechanism of SFN protection against prostate cancer, different stage of prostate cancerous cells were treated with 15muM or 30 muM SFN and harvest 48hr later for MTT assay, HDAC activity and western blot assay. MTT cell proliferation showed that SFN and its metabolites inhibited PC3 prostate cancerous cell growth. SFN also inhibited HDAC activity in prostate cancerous cell alone but not normal cells. SFN selectively induced cell cycle arrest in prostate cancer cells, but not normal prostate cells. SFN treatment reduced the HDAC1 and HDAC3 protein level in PC3 cells and increased the acetylated histone H4. All the study showed that SFN is a HDAC inhibitor and protected against cancer development through epigenetic alteration in prostate cancer cells.
- Medicine and Medical Research